Additional file 1 of A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Makaleler > Tam Makale · 2024
Yazarlar: Lara, Primo N., Villanueva, Luis, Ibanez, Carolina, Erman, Mustafa, Lee, Jae Lyun, Heinrich, Daniel, Lipatov, Oleg Nikolaevich, Gedye, Craig, Gokmen, Erhan, Acevedo, Alejandro, Semenov, Andrey, Park, Se Hoon, Gafanov, Rustem Airatovich, Kose, Fatih, Jones, Mark, Du, Xiaoqi, Munteanu, Mihaela, Perini, Rodolfo, Choueiri, Toni K., Motzer, Robert J.
Figshare, Uluslararası, 2024
DOI: 10.6084/m9.figshare.26377969.v1
Özet
Additional file 1: Supplemental Table 1. List of investigators and institutional review boards. Supplemental Figure 1. Box and whisker plot showing change from baseline to week 3 in serum kynurenine among patients in the both the pembrolizumab plus epacadostat arm and the sunitinib/pazopanib arm. Kynurenine levels at C1D1 and C2D1 were compared using paired t-tests within each treatment arm The dotted line indicates median kynurenine levels in healthy subjects (1.5 μM) [1] Epa , epacadostat, Pembro pembrolizumab, SoC standard of care.